ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2043

Three Distinct Phases in the Amount of Total and Donor-Derived Cell-Free DNA Are Observed over Time in Plasma from Kidney Transplant Recipients

Session Information

Category: Transplantation

  • 1901 Transplantation: Basic

Authors

  • Van Hummelen, Paul, Natera, Inc., San Carlos, California, United States
  • Lee, Soong, Natera, Inc., San Carlos, California, United States
  • Ahmed, Ebad, Natera, Inc., San Carlos, California, United States
  • Gauthier, Philippe, Natera, Inc., San Carlos, California, United States
  • Tabriziani, Hossein, Natera, Inc., San Carlos, California, United States
  • Zimmermann, Bernhard, Natera, Inc., San Carlos, California, United States
  • Billings, Paul Richard, Natera, Inc., San Carlos, California, United States
  • Swenerton, Ryan, Natera, Inc., San Carlos, California, United States
Background

Donor-derived cell-free DNA (dd-cfDNA) is a clinically validated biomarker for allograft rejection in kidney transplant (KT) recipients. Fluctuations in the total amount of cfDNA (including donor and recipient-derived cfDNA) can impact the reported dd-cfDNA fraction. Here we analyzed the changes in total and dd-cfDNA quantity, over time, in KT patients.

Methods

We selected 3,925 samples from 747 clinically stable patients with >3 longitudinal samples. The median time from KT to sample collection was 134 days (range: 1 day - 37 years). Total cfDNA and dd-cfDNA were measured using the ProsperaTM test and expressed as relative units per ml plasma (RU/ml). Dynamic changes in dd-cfDNA and total cfDNA over time were compared to their respective medians for all samples at 3-year post-KT, defined as reference.

Results

One week following KT, median quantities of total cfDNA were elevated ~2-fold above the reference value (494 RU/ml), which normalized over the first month. At month 3, a 1.6-fold increase was observed, which normalized to the reference value over the first year post-KT. In contrast, the absolute quantity of dd-cfDNA was initially elevated ~100-fold above the reference (1.06 RU/ml) post-KT, which normalized over the first month to the reference level where it remained stable. The elevation in dd-cfDNA during the first week is likely due to trauma to the donor organ from surgery. Additionally, a significant elevation in both total and dd-cfDNA was observed in patients who received a kidney from a deceased donor as compared to a living donor.

Conclusion

Total and dd-cfDNA levels were highly dynamic in the first year post-KT but stabilized afterwards. Further investigation is needed to determine the causes of total-cfDNA increases at months 3 and 4. Potential factors include inflammatory responses and NETosis, viral infection or transient interstitial fibrosis and tubular atrophy (IF/TA) in the donor organ. The time dependent dynamics were statistically significant, but with a high coefficient of variance (CV>50%), which limits extrapolations to individual patients. Potential variability should be considered when interpreting dd-cfDNA tests performed within the first week post-KT.